Table 3.
Subgroup analysis of Cox proportional hazard model.
| Occlusion/Dysfunction | Non-Occlusion/Dysfunction | HR | 95% CI | |||
|---|---|---|---|---|---|---|
| N | No. of Cardiovascular Disease | N | No. of Cardiovascular Disease | |||
| Age | ||||||
| 20–65 | 144 | 25 | 59 | 2 | 4.37 | 1.03–18.51 |
| ≥65 | 53 | 6 | 41 | 3 | 1.75 | 0.44–6.99 |
| p for interaction = 0.321 | ||||||
| Gender | ||||||
| Female | 107 | 14 | 51 | 3 | 2.18 | 0.62–7.60 |
| Male | 90 | 17 | 49 | 2 | 4.19 | 0.96–18.22 |
| p for interaction = 0.286 | ||||||
| Warfarin | ||||||
| No | 182 | 27 | 99 | 5 | 2.74 | 1.05–7.14 |
| Yes | 15 | 4 | 1 | 0 | NA | NA |
| Corticosteroids | ||||||
| No | 130 | 27 | 71 | 5 | 2.60 | 0.996–6.77 |
| Yes | 67 | 4 | 29 | 0 | NA | NA |
| Statin | ||||||
| No | 164 | 28 | 92 | 4 | 3.54 | 1.24–10.11 |
| Yes | 33 | 3 | 8 | 1 | 0.89 | 0.09–8.65 |
| p for interaction = 0.285 | ||||||
| Aspirin | ||||||
| No | 168 | 22 | 91 | 4 | 2.64 | 0.91–7.71 |
| Yes | 29 | 9 | 9 | 1 | 2.55 | 0.32–20.13 |
| p for interaction = 0.019 | ||||||